novavax flu vaccine news - Search News

Novavax, FDA and flu vaccine

CNBC on MSN · 4d

Novavax says FDA put hold on combination Covid-flu shot and influenza vaccine; shares plunge

The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a phase two trial.

MarketWatch on MSN · 3d

Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial.

Wall Street Journal · 4d

Novavax Stock Plunges After FDA Pauses Covid, Flu Vaccine Trials

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined Covid-flu vaccine and standalone flu inoculation due to safety concerns. Fi

1don MSN

How Bad Is This News for Novavax?

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

4d

FDA puts Novavax flu vaccine trials on hold

The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 ...

Novavax faces setback as USFDA halts COVID-Flu vaccine trial over nerve damage report

Novavax said a participant enrolled in a mid stage study of the combination vaccine last month reported symptoms of motor ...

3d

Novavax’s Regulatory Setback and Mid-Term Underperformance: An Analyst’s Perspective

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results